Deferred Tax Assets, Valuation Allowance of Lineage Cell Therapeutics, Inc. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Lineage Cell Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • Lineage Cell Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $89,417,000, a 3.6% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Lineage Cell Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $89,417,000 +$3,103,000 +3.6% 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q4 2024 $86,314,000 +$5,801,000 +7.2% 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q4 2023 $80,513,000 +$2,304,000 +2.9% 31 Dec 2023 10-K 05 Mar 2026 2025 FY
Q4 2022 $78,209,000 +$7,242,000 +10% 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q4 2021 $70,967,000 +$6,898,000 +11% 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q4 2020 $64,069,000 +$4,473,000 +7.5% 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q4 2019 $59,596,000 +$21,079,000 +55% 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q2 2019 $1,200,000 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $4,400,000 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $38,517,000 +$31,117,000 +420% 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q4 2017 $7,400,000 +$56,613,000 31 Dec 2017 10-K 12 Mar 2020 2019 FY
Q4 2016 $49,213,000 -$128,026,000 -162% 31 Dec 2016 10-K 15 Mar 2018 2017 FY
Q4 2015 $78,813,000 +$16,969,000 +27% 31 Dec 2015 10-K 16 Mar 2017 2016 FY
Q4 2014 $61,844,000 +$15,723,000 +34% 31 Dec 2014 10-K 15 Mar 2016 2015 FY
Q4 2013 $46,121,000 +$9,220,000 +25% 31 Dec 2013 10-K 11 Mar 2015 2014 FY
Q4 2012 $36,901,000 +$1,961,000 +5.6% 31 Dec 2012 10-K 17 Mar 2014 2013 FY
Q4 2011 $34,940,000 31 Dec 2011 10-K 18 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.